Sobi share new clinical data across multiple hematologic diseases at EHA 2025

"The breadth of data that we share at this year's EHA congress demonstrates Sobi's comprehensive approach to addressing rare conditions in haematology.  We are proud to contribute to advancing the science in several indications from early clinical phases in diffuse large B-cell lymphoma to clinical and real-world evidence in myelofibrosis, primary hemophagocytic lymphohistiocytosis, immune thrombocytopenia and paroxysmal nocturnal haemoglobinuria," said Lydia Abad-Franch, MD, Head of R&D and Medical Affairs, and Chief Medical Officer at Sobi. 

"The breadth of data that we share at this year's EHA congress demonstrates Sobi's comprehensive approach to addressing rare conditions in haematology.  We are proud to contribute to advancing the science in several indications from early clinical phases in diffuse large B-cell lymphoma to clinical and real-world evidence in myelofibrosis, primary hemophagocytic lymphohistiocytosis, immune thrombocytopenia and paroxysmal nocturnal haemoglobinuria," said Lydia Abad-Franch, MD, Head of R&D and Medical Affairs, and Chief Medical Officer at Sobi. 

Key data to be presented at EHA 2025

Session time: 18:30-19:30 CEST

Location: Poster Hall

 

 

Poster presentation

Session title: Poster Session 1
Session date: Friday, 13 June

Session time: 18:30 - 19:30 CEST

Location: Poster Hall

 

Poster presentation

Session title: Poster Session 2
Session date: Saturday, 14 June

Session time: 18:30 - 19:30 CEST

Location: Poster Hall

Publication Only

Published on May 14 at 15:30 CEST

Session time: 18:30 - 19:30 CEST

Location: Poster Hall

Session date: Saturday, 14 June

Session time: 18:30-19:30 CEST

Location: Poster Hall

 

Session time: 18:30 - 19:30 CEST

Location: Poster Hall

Session time: 18:30 - 19:30 CEST

Location: Poster Hall  

 

Session time: 18:30 - 19:30 CEST

Location: Poster Hall

About pegcetacoplan in rare diseases  

Pegcetacoplan is a targeted C3 therapy designed to regulate excessive activation of the complement cascade, a part of the body's immune system, which can lead to the onset and progression of many serious diseases. Pegcetacoplan is under investigation for rare diseases across haematology and nephrology. Pegcetacoplan is approved for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) as EMPAVELI®/Aspaveli® in the United States, European Union, and other countries globally.

About Doptelet® (avatrombopag)

Doptelet® (avatrombopag) is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments, and a treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo an invasive procedure.

About Zynlonta® (loncastuximab tesirine)

Zynlonta® (loncastuximab tesirine) is a CD19-directed antibody drug conjugate (ADC). Zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy.

About Sobi® 

Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at  sobi.com and LinkedIn.

Contacts 
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-share-new-clinical-data-across-multiple-hematologic-diseases-at-eha-2025,c4163132

The following files are available for download:

 

View original content:https://www.prnewswire.co.uk/news-releases/sobi-share-new-clinical-data-across-multiple-hematologic-diseases-at-eha-2025-302480091.html